HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rheumatic Diseases (Rheumatism)

Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
Also Known As:
Rheumatism; Disease, Rheumatic; Diseases, Rheumatic; Rheumatic Disease
Networked: 10402 relevant articles (448 outcomes, 1061 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Rheumatoid Arthritis
2. Pain (Aches)
3. Inflammation (Inflammations)
4. Arthritis (Polyarthritis)
5. Ankylosing Spondylitis

Experts

1. Carmona, Loreto: 30 articles (04/2022 - 08/2003)
2. Sarzi-Puttini, Piercarlo: 27 articles (05/2021 - 01/2009)
3. Smolen, Josef S: 25 articles (01/2021 - 01/2007)
4. Fritzler, Marvin J: 24 articles (01/2021 - 12/2003)
5. Mahler, Michael: 24 articles (01/2021 - 01/2007)
6. Dougados, Maxime: 22 articles (05/2022 - 12/2003)
7. Shoenfeld, Yehuda: 22 articles (11/2021 - 08/2003)
8. Atzeni, Fabiola: 22 articles (10/2021 - 01/2009)
9. Cutolo, Maurizio: 21 articles (02/2022 - 06/2002)
10. Braun, J: 20 articles (11/2021 - 09/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Rheumatic Diseases:
1. Antirheumatic Agents (DMARD)IBA
2. Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
3. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
4. GlucocorticoidsIBA
5. Methotrexate (Mexate)FDA LinkGeneric
6. Etanercept (Enbrel)FDA Link
7. C-Reactive ProteinIBA
04/01/2013 - "The ESPOIR early RA cohort of 813 French patients recruited in 2002-2005 was analyzed to identify patients in remission 6 months after enrollment, according to 2 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria: Boolean ≤ 1 for total tender joint count-28, swollen joint count-28, C-reactive protein, and patient global estimate (PATGL), and Simplified Disease Activity Index (SDAI) ≤ 3.3. "
08/29/2014 - "Both groups demonstrated efficacy through 52 weeks of treatment relative to baseline pretabalumab disease activity based on American College of Rheumatology criteria improvement ≥20%, ≥50% and ≥70%; European League against Rheumatism Responder Index in 28 joints; Disease Activity Score in 28 joints-C-reactive protein; and Health Assessment Questionnaire-Disability Index. "
01/01/2018 - "Secondary efficacy endpoints to week 26 included ACR20/50/70, change from baseline Disease Activity Score based on high-sensitivity C-reactive protein [DAS28-4(CRP)], European League Against Rheumatism (EULAR) response, DAS28-4(CRP) of less than 2.6, and ACR/EULAR remission. "
09/01/2016 - "The treatment target (disease activity score, 4 variables, C-reactive protein (DAS28CRP) ≤3.2 or DAS28>3.2 without swollen joints) was achieved at all visits in ≥85% of patients in year 2; remission rates were DAS28CRP<2.6:69%/66%; Clinical Disease Activity Index ≤2.8:55%/57%; Simplified Disease Activity Index <3.3:54%/49%; American College of Rheumatology/European League against Rheumatism (28 joints):44%/45% (p=0.66-1.00). "
06/01/2013 - "We compared American College of Rheumatology (ACR) 1981 preliminary definition of remission, European League Against Rheumatism (EULAR) disease activity score of 28 joints - C-reactive protein (DAS28 (3)-CRP) and DAS28 (3)-ESR (erythrocyte sedimentation rate) and newer ACR/EULAR remission criteria from 2011. "
8. amsonic acid (DAS)IBA
9. Infliximab (Remicade)FDA Link
10. ametantrone (HAQ)IBA
01/01/2017 - "Univariable logistic regression analysis of potential baseline predictors of European League Against Rheumatism (EULAR) good clinical response, EULAR good/moderate response, 28-joint Disease Activity Score with three variables including the erythrocyte sedimentation rate (DAS28-3V-ESR) remission and Health Assessment Questionnaire (HAQ) response were performed. "
01/01/2010 - "The main outcome measurements included the Health Assessment Questionnaire (HAQ), the Larsen score, and clinical remission according to the American Rheumatism Association (ARA) criteria. "
12/01/2010 - "Treatment effects were estimated using four outcome measures from the included studies: European League Against Rheumatism (EULAR) and ACR20 response rates and mean improvement in disease activity score-28 (DAS-20) and HAQ. "
01/01/2017 - "Regarding clinical results (DAS28-ESR, Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI) low disease activity and remission; ACR20/50/70 and European League Against Rheumatism (EULAR) response; Health Assessment Questionnaire Disability Index (HAQ-DI) score), no relevant differences between monotherapy and combination patients were observed at 1 year. "
01/01/2015 - "The effectiveness of treatment was assessed using the 28-joint Disease Activity Score (DAS28), the Health Assessment Questionnaire (HAQ), measures of remission, the European League Against Rheumatism (EULAR) response during 0-6 months from start of treatment, and survival-on-drug during the first 30 months. "

Therapies and Procedures

1. Therapeutics
2. Biological Therapy
3. Traditional Medicine (Folk Remedies)
4. Drug Therapy (Chemotherapy)
01/01/2023 - "Methods: We investigated patient values (efficacy of drug therapy [effectiveness], safety, economics, daily life, and other) and the continuance rate and disease status of treatment after 6 months in 94 patients with rheumatic disease aged ≥18 years who made decisions with pharmacists and physicians in the pharmacy outpatient clinic between September 2019 and April 2021. "
12/30/2022 - "The study aims to assess patients' beliefs about the necessity and concerns regarding pharmacotherapy in rheumatic diseases and attitude styles, and to investigate the association between clinical factors and negative beliefs about medication. "
01/01/2017 - "Relatively few clinical trials of drug therapies used validated scales: European League Against Rheumatism Sjögren's Syndrome Patient Reported Index was used most often for symptom assessment and 36 Item Short Form Survey for quality of life (QoL). "
01/01/1998 - "The main directions of the study are the development and improvement of diagnostic criteria, the prevalence and incidence of rheumatic diseases among urban and rural populations, at industrial enterprises, in different ethnic groups, genetic and environmental risk factors, disability, the development and introduction of preventive and rehabilitative programmes of drug therapy, etc. A number of combined national programmes was carried out. "
09/22/2023 - "Search terms will combine 4 concepts: rheumatic diseases, drug therapy, pregnancy, and health care administrative data. "
5. Injections